191 related articles for article (PubMed ID: 16380622)
21. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations.
Benamer HT; Oertel WH; Patterson J; Hadley DM; Pogarell O; Höffken H; Gerstner A; Grosset DG
Mov Disord; 2003 Sep; 18(9):977-84. PubMed ID: 14502664
[TBL] [Abstract][Full Text] [Related]
23. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
24. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
25. TechSight. Imaging. A molecular map for neurodegeneration.
Marek K; Seibyl J
Science; 2000 Jul; 289(5478):409-11. PubMed ID: 10939953
[No Abstract] [Full Text] [Related]
26. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
27. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
[TBL] [Abstract][Full Text] [Related]
28. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
29. Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor-ataxia syndrome.
Healy DG; Bressman S; Dickson J; Silveira-Moriyama L; Schneider SA; Sullivan SS; Massey L; Bhatia KP; Shaw K; Bhatia KP; Bomanji J; Wood NW; Lees AJ
Mov Disord; 2009 Jun; 24(8):1245-7. PubMed ID: 19260103
[No Abstract] [Full Text] [Related]
30. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography.
Sedaghat F; Gotzamani-Psarrakou A; Dedousi E; Arnaoutoglou M; Psarrakos K; Baloyannis I; Dimitriadis AS; Baloyannis SJ
Neurodegener Dis; 2007; 4(5):382-5. PubMed ID: 17622781
[TBL] [Abstract][Full Text] [Related]
31. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
Hwang WJ; Yao WJ; Wey SP; Ting G
J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
[TBL] [Abstract][Full Text] [Related]
32. DAT imaging in drug-induced and psychogenic parkinsonism.
Tolosa E; Coelho M; Gallardo M
Mov Disord; 2003 Oct; 18 Suppl 7():S28-33. PubMed ID: 14531043
[TBL] [Abstract][Full Text] [Related]
33. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
34. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Tissingh G; Bergmans P; Winogrodzka A; Stoof JC; Wolters EC; Booij J; Van Royen EA
J Nucl Med; 1997 Aug; 38(8):1271-2. PubMed ID: 9255164
[No Abstract] [Full Text] [Related]
35. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET.
Shinotoh H; Hirayama K; Tateno Y
Adv Neurol; 1993; 60():488-93. PubMed ID: 8420176
[No Abstract] [Full Text] [Related]
36. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease.
Suwijn SR; de Bruin K; de Bie RM; Booij J
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S184-6. PubMed ID: 24262177
[TBL] [Abstract][Full Text] [Related]
37. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
Poewe W; Scherfler C
Mov Disord; 2003 Oct; 18 Suppl 7():S16-21. PubMed ID: 14531041
[TBL] [Abstract][Full Text] [Related]
38. Anterograde Degeneration of the Nigrostriatal Pathway Visualized by 123I-FP-CIT SPECT in a Patient With Artery of Percheron Infarction.
Nakadate M; Miyamoto N; Starkey J; Toriihara A; Tateishi U
Clin Nucl Med; 2016 Jun; 41(6):483-4. PubMed ID: 26914571
[TBL] [Abstract][Full Text] [Related]
39. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders.
Marshall V; Grosset DG
Mov Disord; 2003 Oct; 18 Suppl 7():S22-7. PubMed ID: 14531042
[TBL] [Abstract][Full Text] [Related]
40. Dopamine transporter: basic aspects and neuroimaging.
Piccini PP
Mov Disord; 2003 Oct; 18 Suppl 7():S3-8. PubMed ID: 14531039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
